Cellomics Offers Customers Expanded HCS Training Advanced Courses
These courses will offer customers training for specific uses in biology research and therapeutics, including such fields as oncology, neurobiology and toxicology.
Two classes are scheduled for the fall. HCS 202, to be offered Oct. 25-26, will cover high-content screening applications for cancer research in cell-cycle regulation, apoptosis and necrosis as well as angiogenesis.
The second course, HCS 201, will be held Dec. 5-6, and will teach participants HCS techniques in toxicology focused on cytotoxicity, genotoxicity as well as assays for a broad range of other toxicity indicators.
Additional classes, to be scheduled in the spring, will offer customers training in applications for neurobiology as well as signaling and other areas of cancer research.
"HCS continues to grow from a new technology to an accepted and applied form of cell-based assay screening in the pharmaceutical, biotech and academic arenas," said Dan Calvo, president and chief executive officer of Cellomics.
"The HCS 200 series of courses is an opportunity for scientists to expand their high content analysis knowledge and become power users within their therapeutic discipline."
The HCS 200 series is designed for established users who seek more in-depth training and want to maximize HCS for their therapeutic area, as well as advanced users who are looking for ideas about specific assays that can be automated using HCS.
The advanced courses build on the HCS 101 class, which Cellomics has offered since 2003, providing customers with an introduction to high content screening. 200 customers have completed the introductory course.
All courses are held at Cellomics' dedicated training facility in Pittsburgh, providing participants with hands-on experience with Cellomics automated imaging systems and assays.
Registration and general information on the HCS 200 courses are available on the Cellomics Web site.